Avelumab and Merkel Cell Carcinoma: Examining Biological Plausibility

Legacy of Health Education and Emerging Exposure Concerns

The legacy of general health and science information has long emphasized the importance of understanding how environmental and pharmaceutical exposures interact with biological systems to influence disease risk. This foundational knowledge provides a critical framework for evaluating emerging safety signals in clinical and occupational settings. Within this context, the transition from broad health education to specific exposure concerns requires careful consideration of how therapeutic agents may inadvertently alter disease pathways. Avelumab, a programmed death-ligand 1 inhibitor used in oncology, represents a case where its immunomodulatory effects warrant scrutiny beyond intended therapeutic benefits. In mass production environments, where workers may encounter avelumab through manufacturing processes, the potential for unintended biological interactions becomes a relevant occupational health consideration. The biological plausibility of avelumab exposure influencing Merkel cell carcinoma risk stems from its mechanism of action, which involves disrupting immune surveillance—a process critical for controlling virally mediated cancers. This pivot from general health awareness to occupational exposure concern underscores the need for rigorous monitoring and risk assessment in production settings, ensuring that legacy principles of preventive health are applied to novel pharmaceutical agents.

Avelumab's Mechanism and Therapeutic Context

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096; https://pubmed.ncbi.nlm.nih.gov/33439294). The approval was based on the phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381). However, approximately 50% of patients do not respond or develop immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385).

Biological Plausibility of Avelumab-Induced Merkel Cell Carcinoma

The biological plausibility of avelumab-related MCC causation must be examined in the context of the drug's mechanism and the disease's etiology. Approximately 80% of MCC cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). Avelumab, as an anti-PD-L1 inhibitor, is known to cause overactivation of the immune system, leading to irAEs (https://pubmed.ncbi.nlm.nih.gov/31543781). These irAEs can include a range of inflammatory conditions, such as the reported case of hypercalcaemia secondary to reactivation of sarcoidosis during avelumab treatment for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/31543781). While avelumab is used to treat MCC, the question of whether it can cause or worsen MCC is distinct. The drug's mechanism of action—blocking PD-L1 to enhance T-cell responses—is intended to fight cancer, not induce it. However, in rare instances, immune checkpoint inhibitors have been associated with paradoxical effects, such as hyperprogression or new malignancies, though evidence for avelumab specifically causing MCC is not established in the provided literature. The adequacy of warnings regarding avelumab and MCC is addressed in the drug's prescribing information, which includes risks of irAEs but does not specifically list MCC as a potential adverse effect. The provided evidence does not include any warning labels or regulatory documents that mention MCC as a drug-induced event.

Temporal Relationship and Causation Considerations

For affected patients, causation considerations must weigh the temporal relationship between avelumab exposure and MCC diagnosis. The timeline between exposure and documented harm is critical: avelumab is approved for treating metastatic MCC, meaning patients typically have pre-existing MCC before starting therapy. In the JAVELIN Merkel 200 trial, patients had chemotherapy-refractory metastatic MCC, and avelumab was administered as treatment (https://pubmed.ncbi.nlm.nih.gov/29799096). Therefore, any new or worsening MCC during avelumab therapy would likely be attributed to disease progression rather than drug causation. For patients who develop MCC after avelumab exposure for another indication (e.g., other cancers), the evidence is limited. The provided studies focus on avelumab in MCC patients, not on de novo MCC development in patients treated for other conditions. In avelumab-refractory MCC patients, subsequent treatment with ipilimumab plus nivolumab has shown responses in some cases, indicating that avelumab resistance does not preclude benefit from other checkpoint inhibitors (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/36450381). This suggests that avelumab's effect on the immune system is reversible or can be overcome by alternative immunotherapies.

Risk Assessment and Conclusion

The mechanistic pathways linking avelumab to MCC are not directly causative; rather, avelumab is a therapeutic agent for MCC. The drug's pharmacology involves PD-L1 blockade, which can lead to immune activation and irAEs, but no evidence in the provided snippets supports a mechanism by which avelumab induces MCC. The risk of MCC from avelumab appears negligible based on available data, and the drug's benefit in treating MCC outweighs potential risks. In summary, while avelumab is a key treatment for metastatic MCC, there is no evidence from the provided sources to support a causal link between avelumab exposure and the development of MCC. The biological plausibility is low, as avelumab's mechanism is designed to enhance anti-tumor immunity, not initiate cancer. Warnings appropriately focus on irAEs, and the timeline of exposure typically involves pre-existing MCC. For patients, causation considerations should focus on disease progression rather than drug-induced malignancy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

Based on current evidence, avelumab is not known to cause Merkel cell carcinoma. It is used to treat metastatic MCC, and its mechanism of action enhances anti-tumor immunity. No studies have established a causal link between avelumab exposure and the development of MCC.

What is the biological plausibility of avelumab-related MCC?

The biological plausibility is low. Avelumab blocks PD-L1 to boost T-cell responses against cancer, not to initiate it. While immune checkpoint inhibitors can cause immune-related adverse events, there is no evidence that avelumab induces MCC.

Are there any warnings about MCC in avelumab's prescribing information?

The prescribing information for avelumab includes risks of immune-related adverse events but does not specifically list MCC as a potential adverse effect. No regulatory documents have identified MCC as a drug-induced event.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.